KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) EBITDA: 2014-2024

Historic EBITDA for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Dec 2024 value amounting to -$366.3 million.

  • CRISPR Therapeutics AG's EBITDA fell 45.52% to -$105.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$493.9 million, marking a year-over-year decrease of 122.23%. This contributed to the annual value of -$366.3 million for FY2024, which is 169.26% down from last year.
  • Per CRISPR Therapeutics AG's latest filing, its EBITDA stood at -$366.3 million for FY2024, which was down 169.26% from -$136.1 million recorded in FY2023.
  • CRISPR Therapeutics AG's 5-year EBITDA high stood at $372.7 million for FY2021, and its period low was -$660.8 million during FY2022.
  • Its 3-year average for EBITDA is -$387.7 million, with a median of -$366.3 million in 2024.
  • In the last 5 years, CRISPR Therapeutics AG's EBITDA plummeted by 621.82% in 2020 and then spiked by 206.80% in 2021.
  • Yearly analysis of 5 years shows CRISPR Therapeutics AG's EBITDA stood at -$349.0 million in 2020, then surged by 206.80% to $372.7 million in 2021, then tumbled by 277.30% to -$660.8 million in 2022, then surged by 79.41% to -$136.1 million in 2023, then plummeted by 169.26% to -$366.3 million in 2024.